CONDUIT PHARMACEUTICALS INC.

Murphy Canyon Acquisition Corp. (Nasdaq: MURF), sponsored by Murphy Canyon LLC, completed its initial public offering in 2022 with a focus on the biotech and pharmaceutical sector. In November 2022, MURF announced a definitive business combination agreement with Conduit Pharmaceuticals Inc., a clinical-stage biopharmaceutical company advancing a portfolio of repurposed drug candidates. The transaction has since closed, with Conduit Pharmaceuticals operating as a publicly traded company on Nasdaq following the completed de-SPAC process. For full filing history, deal timelines, and in-depth data on MURF and thousands of other SPAC transactions, sign up for a SpacDesk account at spacdesk.com.

SPAC Counterparty (1)